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Introduction. A neuroimmune communication exists, and compelling evidence suggests that diabetic neuropathy and systemic
inflammation are linked. Our aims were (1) to investigate biomarkers of the ongoing inflammation processes including cytokines,
adhesion molecules, and chemokines and (2) to associate the findings with cardiovascular autonomic neuropathy in type 1 diabetes
by measuring heart rate variability and cardiac vagal tone. Materials and Methods. We included 104 adults with type 1 diabetes.
Heart rate variability, time domain, and frequency domains were calculated from a 24-hour Holter electrocardiogram, while
cardiac vagal tone was determined from a 5-minute electrocardiogram. Cytokines (interleukin- (IL-) 1α, IL-4, IL-12p70, IL-13,
IL-17, and tumor necrosis factor- (TNF-) α), adhesion molecules (E-selectin, P-selectin, and intercellular adhesion molecule-
(ICAM-) 1), and chemokines (chemokine (C-C motif) ligand (CCL)2, CCL3, CCL4, and C-X-C motif chemokine (CXCL)10)
were assessed using a Luminex multiplexing technology. Associations between concentrations of inflammatory biomarkers and
continuous variables of heart rate variability and cardiac vagal tone were estimated using multivariable linear regression
adjusting for age, sex, disease duration, and smoking. Results. Participants with the presence of cardiovascular autonomic
neuropathy had higher systemic levels of IL-1α, IL-4, CCL2, and E-selectin than those without cardiovascular autonomic
neuropathy. IL-1α, IL-4, IL-12, TNF-α, and E-selectin were inversely associated with both sympathetic and parasympathetic
heart rate variability measures (p > 0:01). Discussion. Our results show that several pro- and anti-inflammatory factors, believed
to be involved in the progression of diabetic polyneuropathy, are associated with cardiovascular autonomic neuropathy,
suggesting that these factors may also contribute to the pathogenesis of cardiovascular autonomic neuropathy. Our findings
emphasize the importance of the neuroimmune regulatory system in the pathogenesis of neuropathy in type 1 diabetes.
1. Introduction
There exists a tight integration between the immune and
nervous systems, the so-called inflammatory reflex, capable
of influencing both branches in response to inflammatory
and infectious agitation of homeostasis. Essentially, the auto-
nomic nervous system is implicated in a bidirectional inflam-
matory reflex with the vagal nerve being the main neuronal
substrate of an immunoregulatory role, providing a fast and
subconscious anti-inflammatory response [1, 2]. Through
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activation of the inflammatory reflex, cytokine release
actuates the brain or the vagal afferents directly. Afferent
information is relayed to the brainstem and hypothalamus,
which induces a cholinergic anti-inflammatory reflex medi-
ated by acetylcholine in the vagal efferent branches. Conse-
quently, a deactivation of macrophages and subsequently
inhibition of the synthesis of primarily proinflammatory
cytokines delineate the neuroimmune communication [1–3].
Cardiovascular autonomic neuropathy (CAN) is rela-
tively common in diabetes, and its presence is associated with
increased morbidity and mortality but has not traditionally
been characterized by an inflammatory component [1, 4].
Due to its length, the vagal nerve is particularly vulnerable
to long-term hyperglycaemia and is therefore severely
affected in CAN. Consequently, the inflammatory reflex
may have an implication in the pathogenesis of CAN and
other microvascular complications in diabetes [5]. Heart rate
is the base component for standardized heart rate variability
(HRV) and cardiac vagal tone (CVT). HRV measures the
fluctuations between subsequent heartbeats, indexing neuro-
cardiac function, which can be quantified by the validated
time and frequency domains [6], while CVT is a validated
measure of vagal efferent activity from the brainstem to the
heart [7, 8]. In diabetes, reduced HRV are highly sensitive
for the detection of CAN and precede clinical symptoms [1, 9].
The link between the inflammatory reflex and HRV is
further substantiated in healthy individuals, as endotoxin-
induced subclinical inflammation reduces HRV, while
increased parasympathetic vagal activity decreases cytokine
production [3, 10]. Similar findings have been reported in
type 2 diabetes, although these are highly associated with
the presence of adipose inflammation [4, 11–13]. Systemic
low-grade inflammation has been linked to CAN in long-
term type 1 diabetes [5, 14]; however, in both adolescent
and recent onset diabetes, the inflammatory levels are not
associated with HRV, suggesting that a neurodegenerative
inflammation emerges years after diabetes onset [11, 13].
Hence, inflammatory contributions to the pathogenesis of
CAN likely differs between type 1 and type 2 diabetes. Fur-
thermore, exploration of possible inflammatory mediators
has been limited by the fact that most studies only investigate
acute C-reactive protein, interleukin- (IL-) 6, tumour necro-
sis factor- (TNF-) α, or TNF-α receptors 1 and 2 [5, 14].
However, implementation of multiplexing technologies has
broadened the spectrum of available biomarkers of chronic
low-grade systemic inflammation.
In this study, we hypothesised that increased low-grade
inflammation in adults with long-term type 1 diabetes would
be associated with altered neurocardiac function. Therefore,
we aimed to investigate a broad profile of inflammatory cyto-
kines, adhesion molecules, and chemokines and their associ-
ation with cardiovascular autonomic function assessed with
HRV and CVT.
2. Materials and Methods
2.1. Study Population. The study population consisted of 104
adults with type 1 diabetes recruited from the Department of
Endocrinology at Aalborg University Hospital, Denmark.
Fifty-one had severe distal symmetrical polyneuropathy ver-
ified by abnormal nerve conduction testing, previously
described by Brock et al. [15], while the remaining 53 showed
no clinical signs and symptoms of distal symmetrical poly-
neuropathy. Eligible participants were ≥18 years old, of
Northern European decent with verified type 1 diabetes mel-
litus for more than one year (HbA1c ≥ 6:5%). Participants
were on stable hyperglycemic medication, including long-
acting and fast-acting insulin or insulin pumps with dose
adjustment according to the regimens minimum 1 month
prior to study entry. Exclusion criteria have previously been
described in detail [16]. The study was conducted in accor-
dance with the Declaration of Helsinki, local regulations,
and International Conference on Harmonization Good
Clinical Practice guidelines. The protocol, amendments,
and the informed consent form were approved by The North
Denmark Region Committee on Health Research Ethics,
Denmark (N-20130077 and N-20170045). All subjects gave
their informed consent.
2.2. Heart Rate Variability. Twenty-four-hour electrocardio-
gram was obtained using either a Holter monitor (Lifecard
CF; Del Mar Reynolds, Spacelabs Healthcare, Snoqualmie,
WA, USA) or the extended patch-type Holter monitor
ePatch electrocardiographic Recorder (BioTelemetry Technol-
ogy ApS, Hørsholm, Denmark). The monitor was mounted in
the morning, and assessment of HRV parameters was
computed throughout the 24-hour recording period during
which normal daily activities and routines were allowed.
Data was analyzed using Pathfinder (Software revision B
code; Spacelabs Healthcare) and Cardiscope™ (SmartMedical,
Gloucestershire, United Kingdom), respectively. Time-derived
measures (standard deviation of all normal RR (SDNN),
standard deviation of the averages of RR (SDANN), mean
standard deviation of the averages of RR for each 5-minute
interval (SDNNi), and root mean square of the successive dif-
ferences (RMSSD)) and frequency domainmeasures (very low
frequency (VLF), low frequency (LF), and high frequency
(HF)) were analyzed and interpreted according to interna-
tional guidelines [9].
2.3. Cardiac Vagal Tone. Cardiac vagal tone was obtained
using a simple 3-lead electrocardiography (eMotion Faros
180 device (Bittium, Oulu, Finland)), with electrodes (Ambu
Blue Sensor P, Ballerup, Denmark) placed on the right and
left subclavicular areas and at the cardiac apex. Participants
were asked to refrain from coffee two hours prior to testing,
and the test was conducted following a 5-minute relaxed
period. CVT was computed by the ProBioMetrics online
app version 1.0 (ProBioMetrics, Kent, United Kingdom).
Recording artifacts were defined as a sudden change in two
succeeding heart beats exceeding 15 beats per minute in var-
iation (e.g., coughing or movement), and consequently files
were cleaned by removing five heartbeats before and after,
in order to derive the true CVT. The file was discarded if
the number of edited heartbeats exceeded 20%. Stratification
of participants into CAN–no CAN was based on a CVT cut-
off value of 3.18
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2.4. Serum Concentrations of Inflammation Markers. Blood
samples were drawn from the cubital vein of fasting partici-
pants on the day of examination and centrifuged at
2500 rpm/10 minutes, and serum was stored in -80°C freezer
until analysis were performed. Serum concentrations of
cytokines (interleukin- (IL-) 1α, IL-1β, IL-4, IL-6, IL-8,
IL-10, IL-12p70, IL-13, IL-17A, interferon- (IFN-) α,
IFN-γ, tumor necrosis factor- (TNF-) α and granulocyte-
macrophage colony-stimulating factor (GM-CSF)), adhesion
molecules (E-selectin, P-selectin, and intercellular adhesion
molecule (ICAM)-1), and chemokines (chemokine (C-C
motif) ligand (CCL)2, CCL3, CCL4, and C-X-C motif chemo-
kine (CXCL)10) were analyzed in duplicates by Luminex mul-
tiplexing technology using the Inflammation 20-Plex Human
ProcartaPlex™ Panel (Invitrogen, Thermo Fisher Scientific,
Waltham, MA, USA) and a MAGPIX instrument (Luminex,
Austin, TX, USA), according to the manufacturer’s protocol.
If a sample exceeded three standard deviations from the
group-mean, it was considered an outlier and subsequently
removed before analysis. In addition, if a sample was below
Table 1: Demographic and clinical characteristics among groups.
CAN (CVT ≤ 3:18) %CAN (CVT > 3:18) p value
Age (years) 51 ± 10 41 ± 14 <0.01
Sex (males) 69% 49% 0.09
Body mass index (kg/m2) 27.1 (25.2–30.5) 25.1 (23.3–27.8) 0.02
Current smokers 17% 27% 0.27
Disease duration (years) 32 ± 11 22 ± 11 <0.01
Haemoglobin A1c (mmol/mol) 66 (57–75) 60 (53–69) 0.03
Systolic blood pressure (mmHg) 141 ± 15 132 ± 15 <0.01
Diastolic blood pressure (mmHg) 78 ± 9 74 ± 8 0.06
Heart rate (beats/min) 76 (72–80) 69 (64–75) <0.01
Cholesterol (mmol/L) 4.2 (3.7–4.7) 4.4 (3.8–4.9) 0.42
Long acting insulin dose (IU) 26 (19–38) 24 (18–31) 0.31
Short acting insulin dose (IU) 27 (20–36) 22 (15–28) 0.11
Insulin pump dose (IU) 21.2 (19.9–49.6) 42.4 (32.0–50.0) 0.11
Distal symmetrical polyneuropathy (%) 69% 29% <0.01
SDNN 112 (99–141) 136 (112-167) 0.02
SDANN 103 (88–131) 118 (99–145) 0.04
SDNNi 44 ± 19 57 ± 19 <0.01
RMSSD 20 (13–27) 30 (24–40) <0.01
VLF 1091 (590-1479) 1861 (1184-2907) <0.01
LF 375 (107–576) 968 (509-1580) <0.01
HF 101 (38–197) 268 (141–615) <0.01
Interleukin-1α (pg/mL) 1.0 (0.4–1.2) 0.5 (0.4–0.8) 0.01
Interleukin-4 (pg/mL) 15.9 (12.4–21.6) 7.4 (7.4–12.7) <0.01
Interleukin-12p70 (pg/mL) 46.1 (38.9–65.7) 39.2 (33.2–48.5) 0.02
Interleukin-13 (pg/mL) 3.1 (2.1–4.4) 2.1 (2.1–3.7) 0.12
Interleukin-17A (pg/mL) 10.0 (7.5–15.2) 8.2 (5.9–10.9) 0.02
Tumor necrosis factor-α (pg/mL) 36.9 (22.9–54.5) 27.7 (19.7–38.5) 0.07
C-X-C motif chemokine 10 (pg/mL) 12:4 ± 4:1 11:1 ± 4:0 0.17
C-C motif chemokine ligand 2 (pg/mL) 88.4 (65.2–136.8) 64.2 (41.2–102.2) <0.01
C-C motif chemokine ligand 3 (pg/mL) 14.5 (9.4–22.6) 13.0 (6.4–25.4) 0.54
C-C motif chemokine ligand 4 (pg/mL) 30:2 ± 16:6 31:6 ± 14:1 0.70
E-selectin (ng/mL) 16:8 ± 4:6 14:7 ± 4:4 <0.01
P-selectin (ng/mL) 180.8 (117.0 – 245.9) 143.4 (80.3 – 219.3) 0.06
Intercellular adhesion molecule 1 (ng/mL) 44.6 (26.4–57.4) 39.7 (27.7–57.6) 0.60
Based on normative distribution, data is presented as mean ± SD or median (25th-75th percentiles) for continuous variables and number (%) for binary
variables. p values between the groups (CAN–No CAN) were based on Student’s t-test, the Mann–Whitney U-test, and the chi-squared test. SDNN:
standard deviation of all normal RR; SDANN: standard deviation of the averages of RR: SDNNi: mean standard deviation of the averages of RR for
each 5-minute interval; RMSSD: root mean square of the successive differences; VLF: very low frequency; LF: low frequency; HF: high frequency; UI:
international units.
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the detection level, the sample value was transformed by
dividing the detection level value with the square root of 2
[16]. Readings with a value of zero or with a coefficient of
variation (CV) above 20% between duplicates were excluded
from the dataset.
2.5. Statistics. Data is presented asmean ± SD, median (25th-
75th percentiles), or number (%), dependent on data type and
distribution. We tested for differences between groups
(CAN–no CAN) with Student’s t-test, the Mann–Whitney
U-test, and the chi-squared test. Associations between con-
centrations of inflammatory markers and continuous vari-
ables of HRV and CVT were estimated using multivariable
linear regression models (separate models for the associa-
tions of each of the inflammation markers with each of the
eight variables of cardiovascular autonomic dysfunction)
with increasing complexity (0: unadjusted; 1: adjusted for
age and sex; 2: adjusted for age, sex, and disease duration;
and 3: adjusted for age, sex, disease duration, and smoking).
All statistical analyses were performed using proprietary
software (Stata version 15.0, StataCorp, Texas, USA). Statisti-
cal significance was inferred at a two-tailed p value < 0.01.
Analyses were not adjusted for multiple comparisons and
should therefore be considered exploratory.
3. Results
All participants completed the study with no adverse events;
however, one participant was excluded from the analysis due
to daily consumption of Methotrexate. We successfully mea-
sured six cytokines, three adhesion molecules, and four che-
mokines. The following inflammatory markers could not be
detected or were only detected in very few of the samples:
IL-1β, IL-6, IL-8, IL-10, IFN-α, IFN-γ, and GM-CSF.
3.1. Study Population. Demographic characteristics of the
study participants based on the presence of CAN can be
found in Table 1. No differences were seen between the
groups with respect to sex, BMI, smoking status, HbA1c,
diastolic blood pressure, cholesterol levels, or insulin use.
Participants with the presence of CAN (e.g., lower CVT)
were predominantly males (69% vs 49%), who were older
(51 vs. 41 years), had longer disease duration (32 vs 22 years),
and higher blood pressure (systolic 141 vs 132 and diastolic
78 vs 74) and were more likely to have distal symmetrical
polyneuropathy (69% vs 29%) in comparison to the group
with no CAN (Table 1). Furthermore, they had decreased
time and frequency domain parameters of HRV, namely,
SDNNi (44 vs 57), RMSSD (20 vs 30), VLF (1091 vs 1861),
LF (375 vs 968), and HF (101 vs. 268).
3.2. Systemic Level of inflammatory Markers. Participants
with the presence of CAN had significantly higher systemic
levels of IL-1α, IL-4, CCL2, and E-selectin, than those with
no CAN, whereas the systemic levels of IL-1β, IL-12p70,
IL-13, IL-17A, TNF-α, CXCL10, CCL3, CCL4, P-selectin,
and ICAM-1, though all are numerically higher, did not stat-
ically differ (Figure 1).
3.3. Cytokines and Cardiovascular Autonomic Dysfunction.
Independent of the CAN status, initial unadjusted linear
regression analysis indicated 35 significant inverse associa-
tions between the concentrations of inflammatory cytokines
and parameters of cardiovascular autonomic dysfunction,
with statistically significant associations for all cytokines
(Table 2). However, after adjusting for age and sex (and
subsequently disease duration and smoking), only 15 inverse
associations remained, see Table 2. After adjustments, IL-1α
was associated with SDNNI and RMSSD; IL-4 was associated
with SDNNi, RMSSD, and LF; IL-12p70 was associated with
SDNN, SDNNi, RMSSD, VLF, and LF; and TNF-α was
associated with SDNNi, RMSSD, VLF, LF, and HF. None of
the associations for IL-13 and IL-17A remained after adjust-
ments, neither did the initial association for CVT. Sex
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Figure 1: Increase in inflammatory markers in participants with cardiovascular autonomic neuropathy measured with cardiac vagal tone
below 3.18 (black columns) is compared to those without (cardiac vagal tone above 3.18) (grey columns). The difference is in percentage
compared to those without cardiovascular autonomic neuropathy. ∗p < 0:05 when comparing participants with and without CAN.
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Table 2: Regression analyses of cytokines and neurocardiac.
Unadjusted Adjusted 1 Adjusted 2 Adjusted 3
ρ p R2 p R2 p R2 p
IL-1α
CVT -0.41 <0.001 0.21 0.018 0.24 0.039 0.24 0.052
SDNN -0.34 0.003 0.21 0.030† 0.24 0.026 0.25 0.028
SDANN -0.31 0.006 0.20 0.041† 0.24 0.033 0.24 0.035
SDNNi -0.45 <0.001 0.26 0.002 0.28 0.004 0.28 0.004
RMSSD -0.43 <0.001 0.25 0.003† 0.28 0.004 0.28 0.005
VLF -0.37 0.001 0.21 0.046† 0.24 0.043 0.24 0.048
LF -0.44 <0.001 0.23 0.015 0.25 0.017 0.26 0.018
HF -0.36 0.002 0.21 0.042† 0.24 0.040 0.24 0.048
IL-4
CVT -0.36 0.002 0.15 0.028 0.17 0.054 0.18 0.100
SDNN -0.30 0.006 0.16 0.033‡ 0.19 0.032 0.19 0.035‡
SDANN -0.26 0.016 0.15 0.070‡ 0.18 0.066 0.18 0.069‡
SDNNi -0.36 <0.001 0.20 0.005‡ 0.22 0.008 0.22 0.009‡
RMSSD -0.40 <0.001 0.22 0.002‡ 0.23 0.003 0.23 0.004‡
VLF -0.31 0.005 0.18 0.024‡ 0.20 0.025 0.20 0.030‡
LF -0.33 0.002 0.20 0.007‡ 0.22 0.009 0.22 0.010‡
HF -0.26 0.022 0.15 0.089‡ 0.17 0.103 0.18 0.129‡
IL-12p70
CVT -0.28 0.013 0.09 0.075 0.11 0.128 0.12 0.097
SDNN -0.35 0.001 0.15 0.006 0.19 0.005 0.19 0.006
SDANN -0.30 0.006 0.13 0.018 0.16 0.017 0.17 0.019
SDNNi -0.44 <0.001 0.21 0.000 0.23 0.000 0.24 0.001
RMSSD -0.44 <0.001 0.21 0.000 0.23 0.000 0.24 0.001
VLF -0.37 <0.001 0.17 0.003 0.20 0.003 0.20 0.003
LF -0.41 <0.001 0.20 0.001 0.23 0.001 0.23 0.001
HF -0.33 0.003 0.14 0.016 0.17 0.012 0.18 0.012
IL-13
CVT -0.24 0.042 0.13 0.272‡ 0.14 0.358 0.15 0.295‡
SDNN -0.23 0.037 0.14 0.214‡ 0.16 0.206 0.17 0.193‡
SDANN -0.18 0.120 0.13 0.425‡ 0.15 0.415 0.16 0.406‡
SDNNi -0.31 0.005 0.18 0.034‡ 0.19 0.045 0.20 0.043‡
RMSSD -0.33 0.002 0.19 0.013‡ 0.15 0.017 0.22 0.013‡
VLF -0.24 0.032 0.15 0.132‡ 0.20 0.141 0.18 0.132‡
LF -0.30 0.006 0.19 0.016‡ 0.20 0.020 0.21 0.019‡
HF -0.24 0.032 0.16 0.093‡ 0.17 0.089 0.19 0.070‡
IL-17A
CVT -0.32 0.003 0.13 0.040 0.16 0.077 0.16 0.109
SDNN -0.24 0.022 0.15 0.175‡ 0.19 0.181 0.19 0.185‡
SDANN -0.21 0.046 0.14 0.255‡ 0.18 0.256 0.18 0.259‡
SDNNi -0.34 0.001 0.19 0.012‡ 0.22 0.022 0.22 0.022‡
RMSSD -0.32 0.002 0.19 0.021‡ 0.21 0.033 0.21 0.034‡
VLF -0.28 0.009 0.17 0.074‡ 0.20 0.080 0.20 0.083‡
LF -0.30 0.005 0.18 0.033‡ 0.21 0.044 0.21 0.046‡
HF -0.20 0.069 0.15 0.306‡ 0.18 0.302 0.18 0.314‡
TNF-α
CVT -0.28 0.013 0.15 0.035‡ 0.16 0.068 0.18 0.046‡
SDNN -0.34 0.002 0.19 0.011‡ 0.23 0.011 0.24 0.013‡§
SDANN -0.27 0.015 0.16 0.049‡ 0.20 0.051 0.21 0.060‡§
SDNNi -0.43 <0.001 0.27 0.000‡ 0.29 0.000 0.31 0.000‡
RMSSD -0.47 <0.001 0.29 0.000‡ 0.31 0.000 0.33 0.000‡
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appears to be a contributing factor to the relationship
between HRV parameters and IL-4 or TNF-α, while age was
a contributing factor to the relationship between TNF-α and
LF, and disease duration between TNF-α and HF.
3.4. Adhesion Molecules, Chemokines, and Cardiovascular
Autonomic Dysfunction. Independent of CAN status, initial
unadjusted analysis indicated 13 significant inverse associa-
tions between adhesion molecules or chemokines and param-
eters of cardiovascular autonomic dysfunction (Table 3). After
adjusting for age and sex (and subsequently disease duration
and smoking), only six associations with E-selectin persisted,
indicating the relevance of this endothelial marker, see
Table 3. E-selectin was inversely associated with SDNN,
SDANN, SDNNi, RMSSD, VLF, and LF. Smoking appears
to be a contributing factor to the relationship between
E-selectin and RMSSD.
4. Discussion
In adults with type 1 diabetes, we found that the inflamma-
tory cytokines IL-1α, IL-4, IL-12p70, TNF-α, and the
adhesion molecule E-selectin were inversely associated with
24-hour-derived HRV parameters after adjustments for age,
sex, disease duration, and smoking. These associations were
not found for the 5-minute recordings of CVT. Additionally,
as compared to individuals without signs of CAN, partici-
pants with the presence of CAN had higher systemic levels
of IL-1α, IL-4, CCL2, and E-selectin.
4.1. Both Pro- and Anti-inflammatory Cytokines Associate
with Heart Rate Variability. The existing relationship
between the presence of diabetic neuropathy and proinflam-
matory cytokines, e.g., TNF-α, has been extensively studied.
However, evidence of associations between low-grade
inflammation and CAN is sparse [5, 17]. In animals, proin-
flammatory cytokines IL-1α, IL-1β, and TNF-α are known
contributors to the pathogenesis of neuropathy [18]. It is
likely that similar mechanisms may be involved in the devel-
opment of CAN in humans.
TNF-α is a predominant mediator of proinflammatory
processes, as it activates immune cells to release other proin-
flammatory cytokines. It is primarily produced by activated
macrophages but can also be synthesized by CNS neurons
[2]. It has previously been shown that systemically increased
TNF-α levels are present in type 1 diabetes with increased
blood pressure or cardiovascular disease [19, 20]. Comple-
mentarily,, we found participants with CAN to have
increased levels of TNF-α and a persistent, strong inverse
association between higher levels of TNF-α and decreased
24-hour HRV measures, e.g., SDNNi, RMSSD, VLF, LF,
and HF, confirming previous findings. The 24-hour derived
measures of HRV were expectedly superior and more robust
to detect neurocardiac changes than the 5-minute recording
of CVT, which is a screening measure of putative vagal para-
sympathetic tone.
Chronic hyperglycemia increases TNF-α, interleukins, and
adhesion molecules due to containment of macrophages in a
proinflammatory state [21, 22]. Both TNF-α and IL-1α/β are
neuropoietic cytokines and are as such involved in the patho-
genesis of nerve damage, including phagocytosis and demyelin-
ation. Individuals with type 1 diabetes have decreased neuronal
regenerative potential, e.g., in comparison to healthy and type 2
diabetes, and this toxic combination may reflect the strong
association between HRV measures and proinflammatory
cytokines [23]. However, to our knowledge, no study has inves-
tigated IL-1α in adults with long-term diabetes. IL-1α is
arranged in vesicles within the cell membrane in its mature
form, seldom appearing in systemic circulation and detectable
levels may therefore indicate cell death [24]. We found that
IL-1α was inversely associated with SDNNi and RMSSD.
IL-1α exerts its function essentially similar to IL-1β [24],
and the latter has previously been inversely associated with
changes in HF and RMSSD [18], suggesting a link to CAN.
A novel finding was that the anti-inflammatory cytokines
IL-4 and IL-12p70 were also inversely associated with
SDNNi, RMSSD, and LF, and IL-12p70 furthermore with
SDNN and VLF. Though IL-13 structurally and partly func-
tionally is similar to IL-4, this cytokine was not associated
with HRV measures after adjusting for age and gender,
emphasizing the complexity of the immunoregulatory sys-
tem in diabetes.
4.2. Increased E-Selectin Suggests Epithelial Dysfunction as
Part of Cardiovascular Dysfunction. Adhesion molecules
E-selectin, P-selectin, and ICAM-1 are known biomarkers
of vascular inflammation, expressed by arterial endothelial
cells as an essential part of the chain reaction in differentiat-
ing macrophages from monocytes [13, 25]. E-selectin and
P-selectin have been shown to be increased during the devel-
opment of cardiovascular disease [25]. We found strong and
robust associations between E-selectin and HRV parameters,
Table 2: Continued.
Unadjusted Adjusted 1 Adjusted 2 Adjusted 3
ρ p R2 p R2 p R2 p
VLF -0.35 0.001 0.24 0.002‡ 0.26 0.002 0.28 0.002‡
LF -0.37 <0.001 0.26 0.000‡ 0.28 0.001 0.29 0.001†‡
HF -0.36 <0.001 0.23 0.003‡ 0.26 0.002 0.27 0.003‡§
The table provides rho or R2 and corresponding p values from linear regression models. Bold print indicates statistically significant associations. Adjusted 1:
adjusted for age and sex. Adjusted 2: adjusted for age, sex, and disease duration. Adjusted 3: adjusted for age, sex, disease duration, and smoking. Significant
adjusting factors: †age, ‡sex, §disease duration. IL: interleukin; TNF: tumor necrosis factor; CVT: cardiac vagal tone; SDNN: standard deviation of all normal
RR; SDANN: standard deviation of the averages of RR; SDNNi: mean standard deviation of the averages of RR for each 5-minute interval; RMSSD: root
mean square of the successive differences; VLF: very low frequency; LF: low fre-quency; HF: high frequency.
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Table 3: Regression analyses of chemokines, adhesion molecules, and neurocardiac measures.
Unadjusted Adjusted 1 Adjusted 2 Adjusted 3
ρ p R2 p R2 p R2 p
CXCL10
CVT -0.27 0.015 0.18 0.048‡ 0.21 0.067‡ 0.21 0.087‡
SDNN -0.18 0.114 0.20 0.316†‡ 0.23 0.268‡ 0.23 0.267‡
SDANN -0.15 0.187 0.20 0.379†‡ 0.23 0.307‡ 0.23 0.302‡
SDNNi -0.29 0.008 0.22 0.108†‡ 0.24 0.125‡ 0.25 0.124‡
RMSSD -0.15 0.172 0.20 0.676†‡ 0.22 0.701‡ 0.22 0.713‡
VLF -0.29 0.009 0.22 0.164†‡ 0.24 0.138‡ 0.24 0.142‡
LF -0.28 0.012 0.20 0.557†‡ 0.22 0.521‡ 0.22 0.523‡
HF -0.19 0.091 0.20 0.744†‡ 0.22 0.690‡ 0.22 0.717‡
CCL2
CVT -0.29 0.007 0.12 0.165 0.13 0.210 0.14 0.141
SDNN -0.18 0.088 0.11 0.390† 0.11 0.403 0.14 0.393
SDANN -0.13 0.206 0.11 0.587† 0.11 0.594 0.13 0.602
SDNNi -0.29 0.005 0.14 0.072 0.14 0.085 0.16 0.085
RMSSD -0.29 0.006 0.14 0.069 0.14 0.079 0.16 0.061
VLF -0.30 0.005 0.14 0.074 0.14 0.079 0.16 0.068
LF -0.30 0.004 0.14 0.082 0.14 0.091 0.16 0.086
HF -0.22 0.043 0.11 0.318 0.12 0.324 0.14 0.247
CCL3
CVT -0.18 0.099 0.04 0.196 0.04 0.260 0.10 0.534¶
SDNN -0.05 0.649 0.04 0.984 0.05 0.983 0.10 0.953¶
SDANN -0.02 0.849 0.04 0.826 0.05 0.846 0.10 0.847¶
SDNNi -0.17 0.112 0.05 0.231 0.07 0.298 0.11 0.290¶
RMSSD -0.19 0.069 0.06 0.154 0.07 0.185 0.11 0.234
VLF -0.13 0.227 0.04 0.417 0.06 0.445 0.10 0.490¶
LF -0.17 0.108 0.06 0.182 0.07 0.226 0.11 0.237¶
HF -0.16 0.128 0.05 0.220 0.07 0.213 0.11 0.302
CCL4
CVT -0.26 0.034 0.08 0.025 0.08 0.029 0.08 0.042
SDNN -0.15 0.207 0.03 0.277 0.03 0.277 0.05 0.311
SDANN -0.14 0.221 0.03 0.281 0.03 0.282 0.05 0.310
SDNNi -0.20 0.095 0.04 0.160 0.04 0.164 0.06 0.174
RMSSD -0.08 0.485 0.01 0.666 0.02 0.669 0.03 0.733
VLF -0.10 0.381 0.02 0.618 0.02 0.620 0.04 0.720
LF -0.05 0.685 0.01 0.910 0.01 0.911 0.04 0.877
HF 0.05 0.682 0.03 0.384 0.03 0.386 0.06 0.293
E-selectin
CVT -0.20 0.072 0.04 0.231 0.05 0.319 0.07 0.234
SDNN -0.43 <0.001 0.20 <0.001 0.21 <0.001 0.24 <0.001
SDANN -0.44 <0.001 0.20 <0.001 0.21 <0.001 0.25 <0.001
SDNNi -0.43 <0.001 0.21 <0.001 0.21 <0.001 0.24 <0.001
RMSSD -0.36 <0.001 0.14 0.001 0.15 0.002 0.19 0.001¶
VLF -0.37 <0.001 0.16 0.001 0.17 0.001 0.20 0.001
LF -0.36 <0.001 0.17 0.001 0.17 0.001 0.20 0.001
HF -0.24 0.027 0.08 0.044 0.09 0.043 0.13 0.026
P-selectin
CVT -0.17 0.126 0.07 0.261 0.08 0.313 0.13 0.161
SDNN -0.08 0.480 0.06 0.712 0.08 0.721 0.11 0.813
SDANN -0.06 0.593 0.05 0.791‡ 0.08 0.798 0.11 0.936
SDNNi -0.14 0.194 0.07 0.255‡ 0.09 0.318 0.12 0.377
RMSSD -0.12 0.266 0.06 0.418 0.08 0.484 0.12 0.482
VLF -0.13 0.230 0.07 0.274 0.09 0.281 0.13 0.304
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suggesting an impact of epithelial dysfunction as part of the
microvascular complication leading to CAN in diabetes.
Along the same line, ICAM-1 is a known predictor of car-
diovascular risk [25, 26]. However, Herder et al. found no
association between ICAM and HRV measures in recent
maturity-onset type 1 diabetes [11]. Our results complement
these findings in adults with long-term type 1 diabetes. This
lack of association could possibly reflect general applications
of an intensive treatment regime as standard, as the Diabetes
Control and Complications Trial found levels of ICAM-1
increased over a three-year period during conventional
treatment, in contrast to a decline during intensive insulin
treatment [26].
4.3. Chemotactic Cytokines Are Not Associated with
Cardiovascular Dysfunction. Chemokines play essential roles
in local inflammation, by attracting immune cells to the site
of injury or inflammation [27–29]. Previous studies have
reported CCL2 levels to be independent predictors of cardio-
vascular events [28, 29], and coherently, we found CCL2 to
be increased in participants with CAN. Contradictory, Guan
et al. found no associations between CCL2 levels and auto-
nomic neuropathy in type 1 diabetes; however, they sug-
gested CCL2 to have a role in diabetes complications [27].
The overall lack of association between chemokines and
autonomic parameters may be attributed to the administra-
tion of insulin in type 1 diabetes, which is known to have
anti-inflammatory effects, thereby possibly reducing the
expression of chemokines [29]. Taken together, our results
suggest that the chemokine levels remain unaffected in the
presence of CAN, questioning whether they play a role in
CAN pathogenesis.
4.4. Treatment of Cardiovascular Dysfunction May Impact
the Inflammatory Profile. On account of the evident inter-
twining vagal dysfunction and inflammation, treatment of
either axis may induce an effect on both. Vagal stimulation
through neuromodulation has been suggested as a potential
treatment. Direct vagal nerve stimulation is known to reduce
the proinflammatory response of cytokines including TNF-α
and chemokines effectively in healthy individuals and in
rheumatoid arthritis [23, 24]. Furthermore, beta-blockers
have been shown to influence both the heart rate and inflam-
mation levels [1]. In people with type 1 diabetes and
decreased HRV parameters, intervention for four weeks with
beta-blocker (atenolol) not only increased HRV measures
but also decreased the levels of the inflammatory marker
C-reactive protein [14]. It is therefore plausible that future
mechanism-targeting treatments, e.g., lowering the systemic
level of proinflammatory cytokines, adhesion molecules, and
chemokines ultimately may lead to prevention or treatment
of the neuroinflammatory component in subclinical stages of
CAN. If successful, this would function as an example of
how mechanistic principles can be translated into clinical
practice similar to those applied in the cardiovascular and
nephrological clinics for the benefit of future patients.
4.5. Limitations. This study has a number of limitations.
First, the causation cannot be attributed due to the cross-
sectional design of the study. Furthermore, we were limited
by the measure of the inflammatory markers at a single time
point, which may not accurately reflect average long-term
levels. However, as serum samples and electrocardiograms
were obtained within hours of each other, the results should
at least reflect the acute interaction. Second, although
24-hour HRV is the gold standard within diabetes research
and is known to be reproducible and stable over time, it is
also influenced by cardiac reactions, changing workloads,
and circadian processes [6, 9]. We used two validated
commercially available software programs to analyse HRV
parameters, and concerns have been raised regarding inter-
pretation of the spectral indices as these provide averages of
the modulations attributable to especially the LF and HF
components [9]. Third, although multiplex systems enable
Table 3: Continued.
Unadjusted Adjusted 1 Adjusted 2 Adjusted 3
ρ p R2 p R2 p R2 p
LF -0.13 0.262 0.07 0.232‡ 0.09 0.272 0.13 0.306
HF -0.14 0.212 0.06 0.303 0.09 0.284 0.13 0.272
ICAM-1
CVT -0.22 0.057 0.13 0.265‡ 0.13 0.302‡ 0.13 0.266‡
SDNN -0.12 0.313 0.12 0.729‡ 0.12 0.740‡ 0.13 0.786‡
SDANN -0.07 0.546 0.12 0.977‡ 0.12 0.980‡ 0.13 0.902‡
SDNNi -0.17 0.134 0.13 0.268‡ 0.13 0.310‡ 0.14 0.327‡
RMSSD -0.24 0.031 0.15 0.084‡ 0.15 0.100‡ 0.16 0.099‡
VLF -0.20 0.079 0.14 0.149‡ 0.15 0.157‡ 0.15 0.158‡
LF -0.15 0.184 0.13 0.218‡ 0.14 0.248‡ 0.15 0.258‡
HF -0.20 0.080 0.14 0.141‡ 0.15 0.142‡ 0.16 0.139‡
The table gives rho or R2 and corresponding p values from linear regression models. Bold print indicates statistically significant associations. Adjusted 1:
adjusted for age and sex. Adjusted 2: adjusted for age, sex, and disease duration. Adjusted 3: adjusted for age, sex, disease duration, and smoking. Significant
adjusting factors: †age, ‡sex, §disease duration, ¶smoking. CXCL: C-X-C motif chemokine; CCL: C-C motif chemokine ligand; ICAM: intercellular adhesion
molecule; CVT: cardiac vagal tone; SDNN: standard deviation of all normal RR; SDANN: standard deviation of the averages of RR; SDNNi: mean standard
deviation of the averages of RR for each 5-minute interval; RMSSD: root mean square of the successive differences; VLF: very low frequency; LF: low
frequency; HF: high frequency.
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acquisition of larger quantitative data in a cost-efficient man-
ner, the risk of cross-reactions and the dynamic range of con-
centrations are some of the limitations to this method that
may also hamper direct comparisons with other studies. In
the present study, 7 out of 20 inflammation markers had too
low detection levels to be assessed. Fourth, we used a CVT
cut-off for description of CAN and not the gold standard car-
diovascular autonomic reflex testing, which could result in an
underestimation of the observed differences between the two
investigated diabetic groups. Finally, multiple testing may
have resulted in an inflation of the type 1 error rate. However,
as we have lowered the inferred p value, we believe that our
analyses are informative exploratory, possibly providing a
basis for further research into the pathogenesis of CAN.
5. Conclusions
In conclusion, the obtained results support our hypothesis
that circulating inflammatory factors are associated with
putative sympathetic and parasympathetic HRV measures,
independent of age, sex, disease duration, and smoking. This
suggests that inflammatory factors, believed to be involved in
nerve damage and epithelial dysfunction, may contribute to
the pathogenesis of CAN. Furthermore, the results empha-
size the complexity of the immunoregulatory system in type
1 diabetes.
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